Results 91 to 100 of about 42,265 (195)
Levodopa Efficacy and GLP‐1 Receptor Agonists
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez +3 more
wiley +1 more source
Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy
Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao +8 more
wiley +1 more source
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. [PDF]
Pereira JB +9 more
europepmc +1 more source
Unilateral Freezing of Gait in Normal Pressure Hydrocephalus after Stroke
Movement Disorders Clinical Practice, EarlyView.
Jose Portales +2 more
wiley +1 more source
Abstract Background Emerging evidence implicates neuroinflammation in progressive supranuclear palsy (PSP) pathophysiology, with elevated cyto‐chemokines suggesting natural killer (NK) cell involvement. Methods We characterized peripheral NK in PSP (N = 11) versus Parkinson's disease (PD, N = 10) and healthy controls (HC, N = 8) at both ...
Marina Picillo +11 more
wiley +1 more source
Large-scale activation likelihood estimation meta-analysis of parkinsonian disorders. [PDF]
Ellis EG +6 more
europepmc +1 more source
Abstract Background Blood–brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear. Objectives The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to ...
Jonas Folke +15 more
wiley +1 more source
Detecting Abnormal Eye Movements in Patients with Neurodegenerative Diseases – Current Insights
Akila Sekar,1 Muriel TN Panouillères,2,3 Diego Kaski1 1SENSE Research Unit, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK; 2NeuroClues, Ottignies-Louvain-la-Neuve, Belgium; 3CIAMS, Université Paris-
Sekar A, Panouillères MT, Kaski D
doaj
Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges. [PDF]
Dutta S, Hornung S, Taha HB, Bitan G.
europepmc +1 more source
Macroscale Gradient‐Informed Neural Oscillation Topography in Parkinson's Disease
Abstract Background Parkinson's disease (PD) is characterized by large‐scale disruptions in beta and gamma oscillations. Although subcortical beta power is an established biomarker for current adaptive deep brain stimulation (aDBS), it may not fully capture the global pathophysiological burden and the macroscale hierarchical reorganization of the ...
Hao Ding +8 more
wiley +1 more source

